Literature DB >> 28921484

Reply to the Letter by S. Sorscher Regarding "Implications of BRAF Mutations in dMMR Colorectal Cancers".

R Cohen1, T André2.   

Abstract

ᅟ.

Entities:  

Keywords:  ᅟ

Mesh：

Substances：

Year:  2017        PMID： 28921484     DOI： 10.1007/s11864-017-0505-x

Source DB:  PubMed          Journal:  Curr Treat Options Oncol        ISSN： 1534-6277


× No keyword cloud information.
  3 in total

1.  PD-L1 Studies Across Tumor Types, Its Differential Expression and Predictive Value in Patients Treated with Immune Checkpoint Inhibitors.

Authors:  Harriet M Kluger; Christopher R Zito; Gabriela Turcu; Marina K Baine; Hongyi Zhang; Adebowale Adeniran; Mario Sznol; David L Rimm; Yuval Kluger; Lieping Chen; Justine V Cohen; Lucia B Jilaveanu
Journal:  Clin Cancer Res       Date:  2017-02-21       Impact factor: 12.531

2.  PD-L1 expression in colorectal cancer is associated with microsatellite instability, BRAF mutation, medullary morphology and cytotoxic tumor-infiltrating lymphocytes.

Authors:  Matthew W Rosenbaum; Jacob R Bledsoe; Vicente Morales-Oyarvide; Tiffany G Huynh; Mari Mino-Kenudson
Journal:  Mod Pathol       Date:  2016-05-20       Impact factor: 7.842

3.  Mismatch repair status and BRAF mutation status in metastatic colorectal cancer patients: a pooled analysis of the CAIRO, CAIRO2, COIN, and FOCUS studies.

Authors:  Sabine Venderbosch; Iris D Nagtegaal; Tim S Maughan; Christopher G Smith; Jeremy P Cheadle; David Fisher; Richard Kaplan; Philip Quirke; Matthew T Seymour; Susan D Richman; Gerrit A Meijer; Bauke Ylstra; Danielle A M Heideman; Anton F J de Haan; Cornelis J A Punt; Miriam Koopman
Journal:  Clin Cancer Res       Date:  2014-08-19       Impact factor: 12.531
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.